Welcome to our dedicated page for Sensei Biotherapeutics news (Ticker: SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics stock.
Sensei Biotherapeutics, Inc. develops clinical-stage cancer therapeutics focused on multi-node inhibition of oncogenic pathways. Its lead program, PIKTOR, is an investigational all-oral combination of serabelisib and sapanisertib designed to target PI3K-alpha and dual mTORC1/2 nodes in the PI3K/AKT/mTOR pathway for endometrial and breast cancer. The company also reports on solnerstotug, a V-domain Ig suppressor of T cell activation, or VISTA, inhibitor for advanced solid tumors.
Recurring company news includes oncology trial activity, clinical and regulatory disclosures, operating and financial results, governance updates, capital-structure matters, and Nasdaq inducement equity grants tied to employee compensation.
Sensei Biotherapeutics (Nasdaq: SNSE) completed the Faeth Therapeutics acquisition and a concurrent $200 million private placement, making PIKTOR its lead program.
First patient was dosed in an HR+/HER2- breast cancer Phase 1b/2 trial, with endometrial cancer Phase 2 topline data expected 2H 2026. Q1 2026 cash and securities were $202.8 million, net loss was $170.2 million driven by $133.0 million acquired IPR&D, and stockholders’ equity moved to a $137.3 million deficit alongside $328.5 million Series B redeemable convertible preferred stock.
Sensei Biotherapeutics (Nasdaq: SNSE) dosed the first patient in Study FTH-PIK-101, a Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancer on May 5, 2026. PIKTOR combines oral serabelisib and sapanisertib to target PI3K-alpha and mTORC1/2 simultaneously. The study will evaluate safety and activity of PIKTOR plus fulvestrant and/or other anticancer therapies across HR+/HER2- patients regardless of mutation status. Sensei made PIKTOR its lead program after acquiring Faeth Therapeutics in February 2026. Prior investigator-led data showed a 47% overall response rate and 71% response in PI3K-pathway mutated tumors.
Sensei Biotherapeutics (NASDAQ: SNSE) will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2026 at 12:45 p.m. ET. The presentation will be webcast live and a replay will be available for approximately 90 days via the company investor site.
Sensei Biotherapeutics (Nasdaq: SNSE) completed the acquisition of Faeth Therapeutics and a concurrent $200 million private placement to advance PIKTOR, an all-oral PI3K/AKT/mTOR combination. The financing plus existing cash is expected to support key clinical milestones, with topline data and trial initiation targeted by year-end 2026.
Full year 2025: cash and marketable securities $21.2M; R&D $11.0M; G&A $11.3M; net loss $21.1M or $(16.72) per share.
Sensei Biotherapeutics (Nasdaq: SNSE) announced that on March 11, 2026 its board granted a new employee an option to purchase 166,435 shares as an inducement under Nasdaq Listing Rule 5635(c)(4). The exercise price is $29.37, equal to the March 11, 2026 closing price. The award vests 25% after one year, with the remainder vesting monthly over three years, subject to continued service.
Sensei Biotherapeutics (Nasdaq: SNSE) announced that, effective February 19, 2026, its board granted option awards to 17 new employees totaling 2,319,893 shares as inducements under Nasdaq Listing Rule 5635(c)(4).
The awards include a grant to Anand Parikh of 1,239,305 options, carry an exercise price of $27.22 (equal to the February 19 close), and vest 25% after one year with the remainder vesting monthly over three years, subject to continued service.
Sensei Biotherapeutics (NASDAQ: SNSE) acquired Faeth Therapeutics and its lead asset PIKTOR, and completed a concurrent private placement expected to raise approximately $200 million in gross proceeds. The funds are earmarked to advance PIKTOR through topline Phase 2 data in second-line advanced endometrial cancer and to initiate a Phase 1b trial in HR+/HER2- advanced breast cancer, both expected by year-end 2026, with remaining proceeds for general corporate purposes and completion of Sensei's ongoing solnerstotug Phase 1/2 trial.
Sensei Biotherapeutics (Nasdaq: SNSE) reported third quarter 2025 results and strategic changes on Nov 14, 2025. The board decided to discontinue development of solnerstotug and launched a comprehensive review of strategic alternatives, including asset sales, licensing, collaborations, a sale of the company, merger, or an orderly wind-down.
The company implemented a workforce reduction of approximately 65% and will retain a small team to manage the review, regulatory compliance, and orderly cessation of development activities.
Key financials for the quarter ended Sept 30, 2025: $25.0M cash, cash equivalents and marketable securities (down from $41.3M at Dec 31, 2024); R&D expense $2.5M (vs $4.6M prior year); G&A expense $2.3M (vs $3.2M prior year); net loss $4.6M (vs $7.3M prior year).
Sensei Biotherapeutics (Nasdaq: SNSE) announced on October 30, 2025 that its Board has decided to discontinue development of solnerstotug and has initiated a comprehensive strategic review to maximize shareholder value.
The company said it is evaluating options including asset sales, licensing, collaborations, a sale of the company, merger, business combination, or an orderly wind-down. Sensei expects a workforce reduction to preserve cash and will retain a small team to support the strategic process, regulatory and reporting obligations, and an orderly wind-down of the Phase 1/2 trial. No definitive timeline or assurance of a transaction was provided.
Sensei Biotherapeutics (Nasdaq: SNSE) reported Phase 1/2 dose-expansion results for solnerstotug at ESMO 2025 showing dose-dependent activity and tolerability in PD-(L)1 resistant “hot” tumors.
Key data: 6-month PFS 50% at 15 mg/kg in PD-(L)1 resistant patients versus overall 6-month PFS of 37% across prior PD-(L)1 progressors; six clinical responses occurred at 15 mg/kg including one durable complete response (MCC, 54+ weeks). Safety: six Grade 1 CRS events (all at 15 mg/kg) and no new safety signals (Phase 1 n=98, dose expansion n=64).
Sensei plans Phase 2 trials in 2L NSCLC and PD-(L)1 resistant MCC in 2026, subject to FDA feedback and financing. Investor webcast Oct 20, 2025 at 8:00 AM ET.